Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 30,941 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $14.79, for a total value of $457,617.39. Following the completion of the transaction, the chief operating officer directly owned 647,809 shares in the company, valued at approximately $9,581,095.11. The trade was a 4.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Trading Down 2.9%

Adaptive Biotechnologies stock traded down $0.43 during mid-day trading on Tuesday, hitting $14.52. 1,839,163 shares of the company’s stock were exchanged, compared to its average volume of 1,587,589. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The stock has a 50 day moving average of $16.72 and a two-hundred day moving average of $15.88.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the business earned ($0.23) EPS. The firm’s revenue was up 51.0% compared to the same quarter last year. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the 4th quarter worth $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. grew its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on ADPT shares. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.